J Med Cases
Journal of Medical Cases, ISSN 1923-4155 print, 1923-4163 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Med Cases and Elmer Press Inc
Journal website http://www.journalmc.org

Case Report

Volume 4, Number 2, February 2013, pages 106-108


Methylphenidate Induced Psychotic Symptoms: Two Cases Report

Selma Tural Hesapcioglua, d, Zeynep Gokerb, Cilem Bilginerc, Sema Kandilc

aMus Obstetrics and Gynecology and Child Disorders Hospital, Child and Adolescent Psychiatry Clinic, Mus, Turkey
bAnkara Child Health and Disorders Hematology and Oncology Training and Education Hospital, Child and Adolescent Psychiatry Outpatient Clinic, Ankara, Turkey
cChild and Adolescent Psychiatry Department, Karadeniz Technical University Medical Faculty, Trabzon, Turkey
dCorresponding author: Selma Tural Hesapcioglu Mus Obstetrics and Gynecology and Child Disorders Hospital, Child and Adolescent Psychiatry Clinic, Mus, Turkey

Manuscript accepted for publication October 23, 2012
Short title: Methylphenidate Induced Psychotic Symptoms
doi: https://doi.org/10.4021/jmc923w

Abstract▴Top 

Methylphenidate is a central nervous system stimulant used as the first choice for treating the attention deficit hyperactivity disorder (ADHD). Methylphenidate could rarely cause psychotic symptoms even in with therapeutic doses. In this article, two cases were reported who diagnosed with ADHD, and shortly after the beginning of the long-acting methylphenidate treatment psychotic symptoms has emerged, and was discussed the treatment process of the psychotic symptoms.

Keywords: ADHD; Methylphenidate; Psychotic symptoms

Introduction▴Top 

Methylphenidate is a central nervous system stimulant which using as the first choice for treating the attention deficit hyperactivity disorder (ADHD) [1]. It causes an increase in striatal dopamin signalling by holding dopamine more in synaptic cleft via dopamin transporter blockage and D1 receptor activation in postsynaptic neuron [2]. It has been reported that methylphenidate could rarely cause visual hallucinations, paranoid, somatic or reference delusions in with therapeutic doses [3-7].

The emergence of hallucinations has been attributed to a chronic increase at dopamin levels in synaptic cleft while the pathophysiological mechanisms are not clearly known. In some cases, hallucinations emerged after taking the first and low dose medication has been thought an effect of idiosyncratic mechanism [5].

Stimulants cause an increase of the releasing of catecholamines and a blockage of their getting back. Some authors argues that high dose stimulants can deteriorate the response to the visual stimuli causing different perception of the visual stimuli in susceptible children, based on the information that norepinephrine is released in the lateral geniculate nucleus, and it increases the transmission of visual information [5, 8].

In this article, two cases were reported who diagnosed with ADHD, and shortly after the beginning of the long-acting metylphenidate treatment psychotic symptoms has emerged, and was discussed the treatment process of the psychotic symptoms.

Case Report▴Top 

Case 1

A girl, 10 years of age, had irritability, nervousness, non-compliance complaints for school, inattention, often finding excuses during the lessons. Sometimes suicidal thoughts, struggling in relationships with her mother. She had lost her father when she was 2 years old. Mother described that it is hard to get along with her for childhood period. Weschler Intelligence Scale for Children (WISC-R) verbal score was 107, performance score was 120, total intelligence score was 114. In history there was no any psychotic symptom, no existence in any psychotic symptom or disorder in her family. Attention deficit hyperactivity disorder plus generalised anxiety disorder plus oppositional defiant disorder was diagnosed with the Kiddie-schedule for affective disorders and schizophrenia - present and lifetime version-Turkish version (K-SADS-PL-T) [9] and treated with long-acting methylphenidate 36 mg per day. With the first day of the treatment, the tought which chased by a man continuously who saw him and came eye to eye for just one second with him in a market, watched via a candid camera by him when she was in her home, he wants to harm. During the two weeks period, although had never seen a more, when she was walking she was looking at behind frequently. The evaluation of the Naranjo adverse drug reaction (ADR) probability scale [10] was 8. This symptom was evaluated as an adverse effect of methylphenidate. Methylphenidate were discontinued and began the atomoxetine and it was gradually increased. One week later, the delusion disappeared.

Case 2

A boy, 7.5 years of age, first grade student. While he was taking the first school again he still could not literary. He was hyperactive and fightfull and highly talkative. St Binet IQ was 85. He had never psychotic symptom, there was no family history regarding any psychotic symptom or disorder. DSM-IV [11] criteria it was diagnosed attention deficit hyperactivity disorder and conduct disorder and was began long-acted methylphenidate 18 mg per day treatment. With first dose, the fear which he can be able to harm himself was began. He was seeing the objects as larger-than-life, and also big flies. He has been timid. He was talking to himself, was doing meaningless gesture as if there someone was in the face of him. ADR probability scale score was 7. At the 4th day of after the discontinuation, the fears disappeared. Family did not accept another medication.

Discussion▴Top 

Both cases have complicated ADHD. In both, long-acted methylphenidate treatment [12] were discontinued because it has caused the psychotic symptoms and after discontinuation, symptoms disappeared in a few days.

During the progress of ADHD, bipolar affective disorder or other psychiatric disorders can emerge as comorbid situation [13]. In both cases, comorbid disorder diagnosis was excluded because of the psychotic symptoms has immediately appeared after the methylphenidate treatment and disappeared after discontinuation of it.

Ross showed that the prevalance of the psychotic or manic symptoms emerging after stimulant treatment was 0.25% (or a four hundredth) while some methodological problems. But, it has been argued that reports are insufficient [14].

Kraemer et al. reported that 3 adult cases who had methylphenidat-induced psychotic disorder. After discontinuation and beginning the antipsychotic treatment, all of three patients’ symptoms disappeared [6]. Kraemer et al. argued that the less frequency of psychotic adverse effects due to methylphenidate is stem from the ignorence of this effect by science [6]. In the literature, it has been adressed that the paranoid psychosis can emerge during the treatment of narcolepsia with methylphenidate [6] and it might be possible that the psychotic symptoms can occur because of the abuse of the methylphenidate [15]. In our country, a case emerging visual hallusination after the beginning the methylphenidate and fluoxetine treatment has been reported by Abali ve Mukaddes, in 2007 [16].

Psychotic symptoms emerging after using the methylphenidate treatment is not very frequent and after discontinuation, it can immediately disappear. But this situation, sometimes can be fearful for family and it might be harmful for patient’s compliance to the medication. For all these reasons, clinicians should be aware of psychotic symptoms during the methylphenidate treatment of patient with ADHD, before thinking the any comorbid disorder, clinician should evaluate the methylphenidate adverse effect. Thus, it would gain to clinician the right way of the effective treatment.

Conflict of Interests

Authors have declared that there is not any conflict of interests.


References▴Top 
  1. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, et al. European clinical guidelines for hyperkinetic disorder — first upgrade. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):I7-30.
    doi pubmed
  2. Wilens T, Pelham W, Stein M, Conners CK, Abikoff H, Atkins M, August G, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42(4):424-433.
    doi pubmed
  3. Calello DP, Osterhoudt KC. Acute psychosis associated with therapeutic use of dextroamphetamine. Pediatrics. 2004;113(5):1466.
    doi
  4. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry. 1999;44(8):811-813.
    pubmed
  5. Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidate-induced visual hallucinations. Neuropediatrics. 2011;42(1):30-31.
    doi pubmed
  6. Kraemer M, Uekermann J, Wiltfang J, Kis B. Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol. 2010;33(4):204-206.
    doi pubmed
  7. Halevy A, Shuper A. Methylphenidate induction of complex visual hallucinations. J Child Neurol. 2009;24(8):1005-1007.
    doi pubmed
  8. Young JG. Methylphenidate-induced hallucinosis: case histories and possible mechanisms of action. J Dev Behav Pediatr. 1981;2(2):35-38.
    pubmed
  9. Gokler B, Unal F, Pehlivanturk B, Kultur-Cengel E, Akdemir D, Taner Y. Okul cagi cocuklari icin duygulanim bozukluklari ve sizofreni gorusme cizelgesi-simdi ve yasam boyu sekli-Tuukce uyarlamasinin gecerlik ve guvenirligi. Cocuk ve Genclik Ruh Sagligi Dergisi. 2004;11: 109-116.
  10. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245.
    doi pubmed
  11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th edition, text revised). 2000. Washington, DC.
  12. Marquand AF, De Simoni S, O'Daly OG, Williams SC, Mourao-Miranda J, Mehta MA. Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers. Neuropsychopharmacology. 2011;36(6):1237-1247.
    doi pubmed
  13. Wilens TE, Biederman J, Faraone SV, Martelon M, Westerberg D, Spencer TJ. Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. J Clin Psychiatry. 2009;70(11):1557-1562.
    doi pubmed
  14. Ross RG. Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(7):1149-1152.
    doi pubmed
  15. Akiyama K, Saito A, Shimoda K. Chronic methamphetamine psychosis after long-term abstinence in Japanese incarcerated patients. Am J Addict. 2011;20(3):240-249.
    doi pubmed
  16. Abali O, Mukaddes NM. Methylphenidate induced hallucinations: Case report. Klinik Psikofarmakoloji Bulteni- Bulletin of Clinical Psychopharmacology. 2007; 17: 195-197.


This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Journal of Medical Cases is published by Elmer Press Inc.

 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.